SEC Form 4 · accession 0000899243-18-015554
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Lamattina
Director
Period of report
Jun 6, 2018
Accepted (ET)
Jun 7, 2018 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.79 | Jun 6, 2018 | A | 20,000 | A | — | Jun 6, 2028 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 6, 2019 or the date of the 2019 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.
Remarks
Exhibit 24 - Power of Attorney